UnitedHealth Group (UNH)
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-09-04
$397.14-0.95%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-09-04
Research Workspace
Put UNH beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — annual revenue growth of at least 1%: FY26 revenue guidance $439B vs FY25 $446.75B (-1.7%) vs 1% target.
View ThesisRevenue growth is slowing — up about 6% over the past year and decelerating.
View GrowthRanks among the strongest in its industry on quality — around the top 21%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskUnitedHealth Group's growth has to keep compounding to justify the price. Revenue growth is currently flat, with Q2 FY26 revenue at 0.0% year over year. The stock trades at 21.3× P/E versus a peer median of 22.9×. This suggests the price reflects less growth than forecasted. The primary risk is the broken pillar of annual revenue growth, which fell short of the 1% target. Peer multiples imply a price roughly in line with where it trades. This read is provisional.
Trailing returns as of 2026-09-04. UNH is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 27 analysts currently covering UNH (as of Sep 2026).
Based on 16 Wall Street analysts offering 12-month price targets for UNH in the last 4 months.
Continue this research
Compare UNH with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| UNH Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Managed Health Care — fair value, gap to price, and forward P/E.
Compare the value case
Put UNH next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Maintain disciplined cost management and improve operating margins
Approval barriers removal may impact cost management efforts.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $397.14
The last 12 months of price, then the range of analyst 12-month targets from today’s $397.14.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Advance growth and operational improvements in Optum businesses
Policy change supports growth in Optum businesses.
Advances: Maintain disciplined cost management and improve operating margins
Improved cost management from reduced prior approvals.
Advances: Advance growth and operational improvements in Optum businesses
Targeting prior-authorization removal supports Optum's growth strategy.
Advances: Advance growth and operational improvements in Optum businesses
Unveiling treatments without prior approval boosts Optum's efficiency.
Threatens: Maintain disciplined cost management and improve operating margins
Profit margin discrepancies could impact cost management objectives.
Threatens: Expand UnitedHealthcare consumer base and improve operating margins
Risks in commercial book could hinder consumer base expansion.
Threatens: Maintain disciplined cost management and improve operating margins
IRS fight could impact cost management and margins.
